About Frontier Medicines
Delivering breakthrough medicines for patients by expanding the universe of therapeutic possibilities
Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. We are deploying groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to develop medicines, starting with anti-cancer therapies.
Frontier has prioritized a set of high-impact targets in the development of our wholly-owned precision medicines pipeline. These programs embody our vision of developing precision medicines against important oncology targets that could bring meaningful benefit to patients. Our lead program is FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12C. Mutations in KRASG12C are most prevalent in people with non-small cell lung, colorectal, and pancreatic cancers. In addition, we have a global partnership with AbbVie to discover and develop novel therapies against a defined number of oncology and immunology targets, as well as targeted protein degradation technologies based on novel E3 ligases.